iSpecimen (NASDAQ:ISPC) Stock Price Down 3.7% – What’s Next?

iSpecimen Inc. (NASDAQ:ISPC)’s stock price traded down 3.7% during trading on Thursday . The stock traded as low as $1.83 and last traded at $1.83. Approximately 23,118 shares were traded during trading, a decline of 78% from the average daily volume of 106,162 shares. The stock had previously closed at $1.90.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research report on Friday, July 17th. Wall Street Zen raised shares of iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

iSpecimen Price Performance

The business has a 50 day moving average of $2.63 and a 200 day moving average of $6.67. The firm has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.03 and a beta of 1.63.

iSpecimen (NASDAQ:ISPC) last issued its earnings results on Friday, May 15th. The company reported ($6.66) EPS for the quarter. The firm had revenue of $0.16 million during the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.

Institutional Trading of iSpecimen

A hedge fund recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new position in iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen as of its most recent SEC filing. Hedge funds and other institutional investors own 13.62% of the company’s stock.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.